- Home
- GRC vs COGT Comparison
GRC vs COGT Comparison
Compare GRC & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRC
- COGT
- Stock Information
- Founded
- GRC 1933
- COGT 2014
- Country
- GRC United States
- COGT United States
- Employees
- GRC N/A
- COGT N/A
- Industry
- GRC Fluid Controls
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- GRC Industrials
- COGT Health Care
- Exchange
- GRC Nasdaq
- COGT Nasdaq
- Market Cap
- GRC 942.4M
- COGT 1.0B
- IPO Year
- GRC N/A
- COGT 2018
- Fundamental
- Price
- GRC $32.39
- COGT $4.65
- Analyst Decision
- GRC
- COGT Buy
- Analyst Count
- GRC 0
- COGT 7
- Target Price
- GRC N/A
- COGT $14.17
- AVG Volume (30 Days)
- GRC 77.2K
- COGT 1.2M
- Earning Date
- GRC 04-24-2025
- COGT 05-06-2025
- Dividend Yield
- GRC 2.19%
- COGT N/A
- EPS Growth
- GRC 14.58
- COGT N/A
- EPS
- GRC 1.53
- COGT N/A
- Revenue
- GRC $659,667,000.00
- COGT N/A
- Revenue This Year
- GRC $4.76
- COGT N/A
- Revenue Next Year
- GRC $4.50
- COGT N/A
- P/E Ratio
- GRC $22.12
- COGT N/A
- Revenue Growth
- GRC 0.02
- COGT N/A
- 52 Week Low
- GRC $30.47
- COGT $5.30
- 52 Week High
- GRC $43.79
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- GRC 28.50
- COGT 25.93
- Support Level
- GRC $34.69
- COGT $6.31
- Resistance Level
- GRC $36.32
- COGT $7.49
- Average True Range (ATR)
- GRC 1.02
- COGT 0.37
- MACD
- GRC -0.30
- COGT -0.16
- Stochastic Oscillator
- GRC 19.76
- COGT 0.84
About GRC Gorman-Rupp Company (The)
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.